Literature DB >> 14637010

The economics of public health: financing drug abuse treatment services.

William S Cartwright1, Paul L Solano.   

Abstract

Drug abuse treatment financing exhibits a heterogeneous set of sources from federal, state, and local governments, as well as private sources from insurance, patient out-of-pocket, and charity. A public health model of drug abuse treatment is presented for a market that can be characterized by excess demand in many communities and an implied policy of rationing. According to best estimates, as many as 6.7 million individuals may need treatment, but only an estimated 1.5 million individuals actually participated in treatment episodes. Since, as demonstrated empirically, drug abuse treatment has a robust and positive social net benefit to society, it is perplexing that treatment financing stops with a rationing outcome that inhibits social welfare. The justification for public financing is centered on the external costs of drug addiction, but subsidization is grounded in the reality that a large number of addicted individuals do not have sufficient resources to pay for treatment out-of-pocket, nor do they have private insurance coverage. Social welfare losses are generated by financial arrangements that are inconsistent with rational budgeting theory and as such would lead to non-optimal organization and management of the drug abuse treatment system.

Entities:  

Mesh:

Year:  2003        PMID: 14637010     DOI: 10.1016/s0168-8510(03)00066-6

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  13 in total

1.  Physicians in the substance abuse treatment workforce: understanding their employment within publicly funded treatment organizations.

Authors:  Hannah K Knudsen; Carrie B Oser; Amanda J Abraham; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2012-02-01

2.  Charting a course for health services research at the National Institute on Drug Abuse.

Authors:  Wilson M Compton; Jack B Stein; Elizabeth B Robertson; Denise Pintello; Beverly Pringle; Nora D Volkow
Journal:  J Subst Abuse Treat       Date:  2005-10

3.  Willingness to pay for drug rehabilitation: implications for cost recovery.

Authors:  D Bishai; J Sindelar; E P Ricketts; S Huettner; L Cornelius; J J Lloyd; J R Havens; C A Latkin; S A Strathdee
Journal:  J Health Econ       Date:  2007-12-05       Impact factor: 3.883

4.  Financial factors and the implementation of medications for treating opioid use disorders.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  J Addict Med       Date:  2012-12       Impact factor: 3.702

5.  The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2014-05       Impact factor: 2.582

6.  Nurse turnover in substance abuse treatment programs affiliated with the National Drug Abuse Treatment Clinical Trials Network.

Authors:  Hannah K Knudsen; Amanda J Abraham; Paul M Roman; Jamie L Studts
Journal:  J Subst Abuse Treat       Date:  2010-12-21

7.  Barriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure.

Authors:  Hannah K Knudsen; Amanda J Abraham; Carrie B Oser
Journal:  Eval Program Plann       Date:  2011-03-02

8.  Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations.

Authors:  Hannah K Knudsen; Paul M Roman; Carrie B Oser
Journal:  J Addict Med       Date:  2010-06       Impact factor: 3.702

9.  A 10-year study of factors associated with alcohol treatment use and non-use in a U.S. population sample.

Authors:  Karen G Chartier; Kierste Miller; T Robert Harris; Raul Caetano
Journal:  Drug Alcohol Depend       Date:  2016-01-16       Impact factor: 4.492

10.  Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.

Authors:  Amanda J Abraham; Hannah K Knudsen; Traci Rieckmann; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2013-03       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.